Knights of Columbus Asset Advisors LLC Cuts Position in Sanofi (NASDAQ:SNY)

Knights of Columbus Asset Advisors LLC lessened its holdings in Sanofi (NASDAQ:SNY) by 23.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 3,774 shares of the company’s stock after selling 1,184 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Sanofi were worth $182,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of SNY. Victory Capital Management Inc. increased its stake in shares of Sanofi by 27.6% in the 3rd quarter. Victory Capital Management Inc. now owns 8,669 shares of the company’s stock valued at $500,000 after purchasing an additional 1,876 shares in the last quarter. Prospera Financial Services Inc increased its stake in shares of Sanofi by 5.6% in the 3rd quarter. Prospera Financial Services Inc now owns 11,432 shares of the company’s stock valued at $659,000 after purchasing an additional 604 shares in the last quarter. First Horizon Advisors Inc. increased its stake in shares of Sanofi by 15.6% in the 3rd quarter. First Horizon Advisors Inc. now owns 7,375 shares of the company’s stock valued at $425,000 after purchasing an additional 998 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Sanofi by 4.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 147,955 shares of the company’s stock valued at $8,527,000 after purchasing an additional 6,796 shares in the last quarter. Finally, Banco Santander S.A. increased its stake in shares of Sanofi by 4.4% in the 3rd quarter. Banco Santander S.A. now owns 38,066 shares of the company’s stock valued at $2,194,000 after purchasing an additional 1,604 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on SNY. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. The Goldman Sachs Group began coverage on Sanofi in a research note on Friday. They set a “neutral” rating and a $65.00 price objective for the company. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Price Performance

SNY stock opened at $56.90 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The business has a 50 day simple moving average of $54.55 and a 200-day simple moving average of $52.89. The firm has a market capitalization of $144.40 billion, a PE ratio of 22.85, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a 1 year low of $45.22 and a 1 year high of $60.12.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.